--- title: Sarcomas vs. pharmaceutical science description: "Register now for our live webinar, \"Screening sarcoma drug candidates with certainty,\" and find out how Certis can bring greater certainty to sarcoma drug candidate selection with orthotopic patient-derived xenograft (O-PDX)  models and advanced imaging.  " image: https://whitepapers.certisoncology.com/hubfs/undefined-2.jpeg --- [![CERTIS](https://whitepapers.certisoncology.com/hubfs/certis-lockup-horz-color.svg "CERTIS")](https://www.certisoncology.com/) - [Home](https://www.certisoncology.com/) - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) [Database Login](https://oncointel.certisoncology.com) ![CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) - [Home](https://www.certisoncology.com/) - Drug Developers - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) ![CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com) # Sarcomas vs. pharmaceutical science ###### THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION   ![undefined-2](https://whitepapers.certisoncology.com/hs-fs/hubfs/undefined-2.jpeg?width=206&name=undefined-2.jpeg) **[  Join us](https://us02web.zoom.us/webinar/register/WN_YnjZRouASsWZvkol9R3Rnw) for a 20-minute lunch & learn, followed by a Q&A session.**  *  What:* Live webinar, “Screening Sarcoma Drug Candidates with Certainty” *  When:* June 29, 2021, 12pm – 12:30pm (PST)      Sourcing the right tumors to support your pharmaceutical company’s sarcoma drug pipeline can often be a difficult part of preclinical development. Certis leverages more clinically relevant models — orthotopic patient-derived xenograft (O-PDX) — and advanced imaging technologies to optimize lead candidate selection, and bridge the translational gap.     Discover a true preclinical partnership with Certis scientists who have deep expertise in the molecular pathways, biology and treatment of sarcomas.     [![Register now](https://no-cache.hubspot.com/cta/default/7965310/9e12fdcb-ec58-408c-a80b-e8dc9bcacb17.png)](https://cta-redirect.hubspot.com/cta/redirect/7965310/9e12fdcb-ec58-408c-a80b-e8dc9bcacb17)   ###### **Upcoming Sarcomas CertiScreen**  Plus, get a sneak peek at an opportunity to join our upcoming Sarcoma CertiScreen—a faster, more cost-efficient path to certainty that will include 21 of our best-in-class tumor models.    ###### **Certis TumorBank: Sarcoma tumor models** **![sarcoma-characterization](https://whitepapers.certisoncology.com/hs-fs/hubfs/sarcoma-characterization.png?width=500&name=sarcoma-characterization.png)** - 63 highly characterized sarcoma tumor models  - 23 matched cell cultures, some with TILS  - Biomarkers of interest: 7 with 12q15 region amplification, CDK4 and MDM2 gene amplification detected [Back to Feed](https://blog.certisoncology.com) ### Share This ![Certis](https://whitepapers.certisoncology.com/hubfs/certis-logo-lockup-white.svg "Certis") 5626 Oberlin Drive, Suite 110 San Diego, CA 92121 Drug Development: 858-988-1033 Patients & Oncologists: 858-228-4110 Main: 858-952-1820 - #### Drug Developers - [CertisAI™](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies) - [Custom Model Development](https://www.certisoncology.com/for-drug-developers/custom-model-development) - [In Vitro/Ex Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology) - [In Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology) - [Imaging/Endpoint Analysis](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - #### Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - #### Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research) - [Media](https://www.certisoncology.com/resources/media) - [White Papers](https://news.certisoncology.com/) - #### About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values) - [Team](https://www.certisoncology.com/about-us/our-team) - [Our Story](https://www.certisoncology.com/about-us/our-story) - [Careers](https://www.certisoncology.com/about-us/careers) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us) - [Login](https://oncointel.certisoncology.com) - [Privacy Policy](https://www.certisoncology.com/privacy-policy) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--facebook.svg)](https://www.facebook.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--linkedin.svg)](https://www.linkedin.com/company/certis-oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--twitter.svg)](https://twitter.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--instagram.svg)](https://www.instagram.com/certis_oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--youtube.svg)](https://www.youtube.com/channel/UCeX4_jh3RlNKxQxZ89_utjg) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--blog.svg)](https://blog.certisoncology.com/) ![certis-footer-mouse](https://whitepapers.certisoncology.com/hubfs/certis-footer-mouse.svg "certis-footer-mouse") --- ©2024 Certis Oncology Solutions. All rights reserved. Testimonials appearing on this site reflect real-life experiences of those who have used our services. To protect their privacy, photos feature models. ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Elie J. Diner, Ph.D.", "url" : "https://whitepapers.certisoncology.com/author/elie-j.-diner-ph.d" }, "dateModified" : "2021-06-02T18:49:11.577Z", "datePublished" : "2021-06-02T17:00:00.000Z", "headline" : "Sarcomas vs. pharmaceutical science", "image" : [ "https://whitepapers.certisoncology.com/hubfs/undefined-2.jpeg" ], "mainEntityOfPage" : { "@id" : "https://whitepapers.certisoncology.com/sarcomas-vs.-pharmaceutical-science", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://whitepapers.certisoncology.com/hubfs/certis-logo-lockup_sig-1.png" }, "name" : "Certis Oncology Solutions" } } ```